Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0831 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| MK0831 | DRUG | - |
Inclusion Criteria: * Not tolerating current ART regime laboratory status is stable * Able to take oral liquid medications but have difficulty swallowing capsules * Weigh at least 10 kg (22 lbs) Exclusion Criteria: * Has had more than 2 episodes of moderate to severe diarrhea or vomiting lasting ...
Top 20 of 28 competitors
MK0831 is an investigational small molecule being developed for the treatment of HIV Infections. It is currently in Phase 3 clinical development, though the only listed trial is a completed expanded access program, meaning it remains under investigation and is not yet approved.
MK0831 is being developed by Merck & Company, Inc., which trades under the ticker MRK. The company is conducting clinical research on this investigational small molecule for HIV Infections.
MK0831 is in Phase 3 clinical development for HIV Infections. The single trial listed is a completed Phase 3 expanded access program, and the drug remains investigational, meaning it has not been approved by regulatory authorities.
MK0831 has one completed clinical trial, NCT00543530, titled "Pediatric Expanded Access Program-Oral Solution (0831-908)." This Phase 3 study enrolled pediatric patients aged 3 years and older with HIV Infections and was an uncontrolled, open-label expanded access program.
MK0831 is not FDA approved. It is an investigational drug in Phase 3 clinical development for HIV Infections. The only listed trial is a completed expanded access program, which does not constitute approval, and the drug remains under clinical investigation.